Abciximab beneficial in younger patients with ACS undergoing PCI

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1569, 2007-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Eptifibatide worthwhile in patients undergoing PCI

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 351, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Abciximab: benefits for some in ACS

Inpharma, Vol. 1, Iss. 1535, 2006-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 493, 2005-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Clinical outcomes are similar for abciximab and eptifibatide in patients who undergo percutaneous coronary intervention (PCI), but abciximab is associated with greater costs

Inpharma, Vol. 1, Iss. 1518, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Clopidogrel cost effective in patients undergoing PCI

Inpharma, Vol. 1, Iss. 1520, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite